NO983288L - Behandling av urininkontinens med nitrogenoksidsyntase-substarter og/eller nitrogenoksid-derivater - Google Patents

Behandling av urininkontinens med nitrogenoksidsyntase-substarter og/eller nitrogenoksid-derivater

Info

Publication number
NO983288L
NO983288L NO983288A NO983288A NO983288L NO 983288 L NO983288 L NO 983288L NO 983288 A NO983288 A NO 983288A NO 983288 A NO983288 A NO 983288A NO 983288 L NO983288 L NO 983288L
Authority
NO
Norway
Prior art keywords
nitric oxide
substitutes
treatment
urinary incontinence
derivatives
Prior art date
Application number
NO983288A
Other languages
English (en)
Other versions
NO983288D0 (no
Inventor
Robert E Garfield
Kristof Chwalisz
Original Assignee
Schering Ag
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Ag, Univ Texas filed Critical Schering Ag
Publication of NO983288D0 publication Critical patent/NO983288D0/no
Publication of NO983288L publication Critical patent/NO983288L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/295—Iron group metal compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Materials For Medical Uses (AREA)
  • Absorbent Articles And Supports Therefor (AREA)
NO983288A 1996-01-18 1998-07-16 Behandling av urininkontinens med nitrogenoksidsyntase-substarter og/eller nitrogenoksid-derivater NO983288L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/588,586 US5789442A (en) 1996-01-18 1996-01-18 Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors alone or in combination with estrogen or progesterone and/or other agents
PCT/US1997/000795 WO1997025984A1 (en) 1996-01-18 1997-01-21 Treatment of urinary incontinence with nitric oxide synthase substrates and/or nitric oxide donors

Publications (2)

Publication Number Publication Date
NO983288D0 NO983288D0 (no) 1998-07-16
NO983288L true NO983288L (no) 1998-09-17

Family

ID=24354466

Family Applications (1)

Application Number Title Priority Date Filing Date
NO983288A NO983288L (no) 1996-01-18 1998-07-16 Behandling av urininkontinens med nitrogenoksidsyntase-substarter og/eller nitrogenoksid-derivater

Country Status (14)

Country Link
US (2) US5789442A (no)
EP (1) EP0874627A1 (no)
JP (1) JPH11512748A (no)
KR (1) KR19990077337A (no)
CN (1) CN1208346A (no)
AU (1) AU721998B2 (no)
BR (1) BR9707026A (no)
CZ (1) CZ224398A3 (no)
NO (1) NO983288L (no)
NZ (1) NZ330471A (no)
PL (1) PL327823A1 (no)
SK (1) SK91798A3 (no)
WO (1) WO1997025984A1 (no)
ZA (1) ZA97458B (no)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997026876A1 (en) * 1996-01-29 1997-07-31 Eli Lilly And Company Methods of increasing sphincter competence
US6469065B1 (en) 1996-02-02 2002-10-22 Nitromed, Inc. Nitrosated and nitrosylated α-adrenergic receptor antagonist, compositions and methods of use
US20020143007A1 (en) * 1996-02-02 2002-10-03 Garvey David S. Nitrosated and nitrosylated alpha-adrenergic receptor antagonists, compositions and methods of use
US20050065161A1 (en) * 1996-02-02 2005-03-24 Nitromed, Inc. Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
US6323211B1 (en) 1996-02-02 2001-11-27 Nitromed, Inc. Compositions and methods for treating sexual dysfunctions
US6294517B1 (en) 1996-02-02 2001-09-25 Nitromed, Inc. Compositions and kits comprising alpha-adrenergic receptor antagonists and nitric oxide donors and methods of use
IT1288123B1 (it) * 1996-09-04 1998-09-10 Nicox Sa Uso di nitroderivati per l'incontinenza urinaria
US6207713B1 (en) * 1997-09-17 2001-03-27 Eric T. Fossel Topical and oral delivery of arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US6472425B1 (en) 1997-10-31 2002-10-29 Nitromed, Inc. Methods for treating female sexual dysfunctions
EP1175210A4 (en) 1999-03-19 2003-07-09 Enos Pharmaceuticals Inc STRENGTHENING THE BIODAVAILABILITY OF DRUGS IN THE BRAIN
FR2794647A1 (fr) * 1999-06-11 2000-12-15 Centre Nat Rech Scient Compositions pharmaceutique comprenant du no ou au moins un compose capable de liberer ou d'induire la formation de no dans les cellules
IL149422A0 (en) * 1999-11-03 2002-11-10 Smith Howard J & Ass Pty Ltd Oral pharmaceutical compositions for liver therapy
US6436428B1 (en) * 2000-03-21 2002-08-20 Enhance Pharmaceuticals, Inc. Device and method for treating urinary incontinence in females
AUPQ968700A0 (en) * 2000-08-28 2000-09-21 Intreat Pty Limited Treatment of urinary incontinence
IL145838A (en) * 2000-10-16 2008-11-03 Pfizer Prod Inc Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
WO2002036144A1 (en) * 2000-10-30 2002-05-10 University Of Zurich Gnrh analogues for treatment of urinary incontinence
GB0030580D0 (en) * 2000-12-15 2001-01-31 Medicare Man Consultancy Ltd Composition and method
AU2006234422B2 (en) * 2001-12-20 2008-08-21 Femmepharma Holding Company, Inc. Vaginal delivery of drugs
JP2005513080A (ja) * 2001-12-20 2005-05-12 フェムファーマ， インコーポレイテッド 薬物の膣送達
DE60302454T2 (de) 2002-04-19 2006-08-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Beta-agonisten-verbindungen mit stickoxid-donatoren-gruppen und reaktionsfähige sauerstoffspezies-fängergruppen und ihre verwendung bei der behandlung von atemwegsstörungen
HK1079997A1 (zh) * 2002-04-26 2006-04-21 舍林股份公司 治疗接受激素替代疗法之妇女中的高血压的方法
FR2842108B1 (fr) 2002-07-09 2008-05-02 Effik Composes a base d'hormone et de monoxyde d'azote et leur utilisation en obstetrique et en gynecologie
US20080145424A1 (en) * 2002-10-24 2008-06-19 Enos Phramaceuticals, Inc. Sustained release L-arginine formulations and methods of manufacture and use
CA2503284A1 (en) * 2002-10-24 2004-05-06 Enos Pharmaceuticals, Inc. Sustained release l-arginine formulations and methods of manufacture and use
US7786101B2 (en) * 2002-11-05 2010-08-31 Bayer Schering Pharma Ag Cardiovascular protection using anti-aldosteronic progestins
DE60333228D1 (de) * 2002-12-02 2010-08-12 Amgen Fremont Inc Gegen den tumor nekrose faktor gerichtete antikörper und deren verwendungen
MXPA05007266A (es) * 2003-01-02 2006-01-17 Femmepharma Holding Co Inc Preparaciones farmaceuticas para tratamientos de enfermedades y trastornos del seno.
US9173836B2 (en) 2003-01-02 2015-11-03 FemmeParma Holding Company, Inc. Pharmaceutical preparations for treatments of diseases and disorders of the breast
AU2004279298B2 (en) * 2003-09-29 2009-01-29 Palmetto Pharmaceuticals, Llc Sustained release L-arginine formulations and methods of manufacture and use
US20060148782A1 (en) * 2003-11-10 2006-07-06 Lundeen James E Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20050220825A1 (en) * 2004-03-10 2005-10-06 Adrian Funke Molecular dispersions of drospirenone
MY142989A (en) * 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
BRPI0508612A (pt) 2004-03-10 2007-08-14 Schering Aktiengellschaft composições compreendendo drospirenona dispersa molecularmente
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20090105336A1 (en) * 2004-04-19 2009-04-23 Strategic Science & Technologies, Llc Beneficial Effects of Increasing Local Blood Flow
WO2005102307A2 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
EP1853272A1 (en) * 2005-02-03 2007-11-14 Duramed Pharmaceuticals, Inc. Compositions of unconjugated estrogens and methods for their use
WO2007076144A2 (en) * 2005-12-27 2007-07-05 Duramed Pharmaceuticals, Inc. Conjugated estrogen compositions, applicators, kits, and methods of making and use thereof
CA2637608A1 (en) * 2006-01-20 2007-07-26 Pear Tree Pharmaceuticals, Inc. Method of treating atrophic vaginitis
JP5193196B2 (ja) 2006-06-02 2013-05-08 ペア ツリー ウーマンズ ヘルス ケア 萎縮性膣炎の治療の方法
EP2104489A2 (en) * 2006-12-26 2009-09-30 FemmePharma Holding Company, Inc. Topical administration of danazol
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US20110003000A1 (en) * 2009-07-06 2011-01-06 Femmepharma Holding Company, Inc. Transvaginal Delivery of Drugs
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
EP4491225A3 (en) 2010-12-29 2025-03-26 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150313956A1 (en) * 2014-05-05 2015-11-05 Napier Consulting Llc Compositions and methods for hair growth
RU2016143081A (ru) 2014-05-22 2018-06-26 Терапьютиксмд, Инк. Натуральные комбинированные гормонозаместительные составы и терапии
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
US9931349B2 (en) 2016-04-01 2018-04-03 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN113633611B (zh) * 2020-05-11 2024-08-27 鲁南制药集团股份有限公司 一种己酸羟孕酮混悬注射液及其制备方法
AU2020480974A1 (en) 2020-12-07 2023-07-13 Kimberly-Clark Worldwide, Inc. Methods and consumer products for detecting a metabolite

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260276A (en) * 1991-06-14 1993-11-09 Warner-Lambert Company Linear and monocyclic endothelin antagonists
GB9123967D0 (en) * 1991-11-12 1992-01-02 Fujisawa Pharmaceutical Co New compound and its preparation
US5378715A (en) * 1992-02-24 1995-01-03 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
WO1993025580A1 (en) * 1992-06-18 1993-12-23 Immunopharmaceutics, Inc. Cyclic peptides that modulate endothelin activity
US5508045A (en) * 1992-10-09 1996-04-16 The Regents Of The University Of California Method and agents for control and management of labor during pregnancy
GB9313330D0 (en) * 1993-06-28 1993-08-11 Fujisawa Pharmaceutical Co New compound and its preparation
US5595970A (en) * 1993-07-16 1997-01-21 Schering Aktiengesellschaft Treatment of climacteric disorders with nitric oxide synthase substrates and/or donors
US5895783A (en) * 1993-07-16 1999-04-20 Schering Aktiengesellschaft Treatment of preeclampsia and preterm labor with combination of progestational agent and a nitric oxide synthase substrate and/or donor
WO1995006466A1 (en) * 1993-09-01 1995-03-09 Koren Laboratories Pty. Limited Treatment of anorectal disorders
SK63396A3 (en) * 1993-11-16 1997-03-05 Schering Ag Treatment of uterine contractility disorders with a nitric oxide synthase substrate and/or donor, or a nitric oxide inhibitor

Also Published As

Publication number Publication date
NZ330471A (en) 2000-10-27
AU1703197A (en) 1997-08-11
WO1997025984A1 (en) 1997-07-24
EP0874627A1 (en) 1998-11-04
JPH11512748A (ja) 1999-11-02
AU721998B2 (en) 2000-07-20
BR9707026A (pt) 1999-07-20
US5789442A (en) 1998-08-04
KR19990077337A (ko) 1999-10-25
PL327823A1 (en) 1999-01-04
CN1208346A (zh) 1999-02-17
CZ224398A3 (cs) 1999-03-17
NO983288D0 (no) 1998-07-16
ZA97458B (en) 1998-07-14
US6028106A (en) 2000-02-22
SK91798A3 (en) 1999-12-10

Similar Documents

Publication Publication Date Title
NO983288L (no) Behandling av urininkontinens med nitrogenoksidsyntase-substarter og/eller nitrogenoksid-derivater
NO961994D0 (no) Behandling av klimakteriske forstyrrelser med nitrogenoksidsyntasesubstrater og/eller -donorer
NO985896L (no) Behandling av urininkontinens ved bruk av (S)-oksybutynin og (S)-desetyloks
FI973357A0 (fi) Verisuonen tromboosin ja uudelleen ahtautumisen hoito sisään hengitetyllä typpioksidilla
NO994778L (no) Fremgangsmåter og preparater for behandling av inflammatorisk tarmsyndrom
DE69722720D1 (de) Ballonkatheter und Methode zur Anwendung
EP1073496A4 (en) IRRADIATION CATHETER AND APPLICATION METHOD
NO941679D0 (no) Gallesyrederivater, fremgangsmåte for fremstilling og deres anvendelse
FI971969A0 (fi) Peräpukamien hoitoon tarkoitettuja koostumuksia ja käyttömenetelmä
NO995310L (no) Stent med radioaktivt overflatebelegg, fremgangsmåte for fremstilling av denne og anvendelse av denne ved restenoseprofylakse
DE69718399D1 (de) Dilatations- und Zentrierungskatheter
HUP9904361A3 (en) Use of isobutylgaba and its derivatives for the treatment of pain
EP0924983A4 (en) S (-) - TOLTERODINE FOR THE TREATMENT OF URINARY AND GASTROINTESTINAL DISORDERS
IL149078A0 (en) Modified plant viruses and methods of use thereof
GB2320565B (en) Furnace pyrometers and methods of measuring furnace temperatures
AU2990497A (en) Methods and means of detecting nitric oxide synthase
FI951858L (fi) Kinoloni- ja akridonijohdannaisia virtsanpidätyskyvyttömyyden hoidossa
NO970582D0 (no) Fremgangsmåte og blandinger nyttige i protylakse og behandling av endotoksin-relaterte tilstander
NO984836L (no) Substituerte benzylaminer og deres anvendelse for behandling av depresjon
DE59710130D1 (de) Verwendung verbindungsverfahrens und verbindungsverfahren
DK118995A (da) Hjulnav med affjedring og anvendelse af sådant hjulnav
DE69406837D1 (de) Gaslanze und Verwendungsverfahren
FI954138L (fi) Hydroksimetyylifuratsaanikarboksyylihappojohdannaiset ja niiden käyttö sydänverisuonitautien käsittelyssä
AU3086097A (en) Nitric oxide inhalation for the prophylaxis and treatment of inflammatory response
AU2705495A (en) Use of rooperol and hypoxoside and their derivatives in the treatment of inflammatory

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application